Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104013 · ClinicalTrials.gov registry record · Phase 3
Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,455
- Enrollment target
NCT00104013 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,455 participants.
The verdict
NCT00104013, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,455 participants
- Enrollment target
Study Summary
The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance pill).
Interventions
- DRUG xaliproden (SR57746A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,455 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104013
The ClinicalTrials.gov registry entry for NCT00104013 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which xaliproden (SR57746A) is the first listed.
NCT00104013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104013 about?
NCT00104013 is a clinical study titled "Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type". The purpose of this study is to assess xaliproden's potential capacity of slowing the deterioration of cognitive and global functions in patients with mild to moderate Alzheimer's disease. The patients participating in this study will take orally once daily xaliproden or placebo (inactive substance ...
What is the current status of trial NCT00104013?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,455 participants. The study started on 2003-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00104013?
The interventions under investigation include: xaliproden (SR57746A) (DRUG).
Who is sponsoring clinical trial NCT00104013?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.